GenSight Biologics to Present at Upcoming Medical Conferences and Stakeholder Meetings - June 04, 2024

2024-06-04
基因疗法临床研究
PARIS--(BUSINESS WIRE)-- Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced its participation at key medical and stakeholder meetings in the remainder of 2024. On June 4, three papers on LUMEVOQ®, the company’s gene therapy for Leber Hereditary Optic Neuropathy (LHON, will be presented at the 16th Meeting of the European Neuro-Ophthalmology Society (EUNOS), which is being held in Rotterdam, the Netherlands, from June 3 - 6, 2024. Presentation: “Efficacy and Safety of Lenadogene Nolparvovec Gene Therapy for Leber Hereditary Optic Neuropathy in the Real-Life Setting” Type: Poster Presenter: Catherine Vignal, MD, Quinze-Vingts National Eye Hospital, Paris, France Time: Poster Session 1, Tuesday, June 4, 2024, from 1:00 - 2:00 pm CEST Location: Poster Area – Poster P-099 Presentation: “Meta-Analysis of Treatment Outcomes for Patients With m.11778G>A MT-ND4 Leber Hereditary Optic Neuropathy” Type: Poster Presenter: Nancy J. Newman, MD, Emory University School of Medicine, Atlanta, USA Time: Poster Session 1, Tuesday, June 4, 2024, from 1:00 - 2:00 pm CEST Location: Poster Area – Poster P-101 Presentation: “Ocular Post-Mortem Analyses with Histopathological and Molecular Assessments in LHON Following AAV2 Gene Therapy” Type: Poster Presenter: Valerio Carelli, University of Bologna and IRCCS Istituto delle Scienze Neurologiche, Ospedale Bellaria, Italy Times: Poster Session 1, Tuesday, June 4, 2024, from 1:00 - 2:00 pm CEST Rapid Fire Poster Session, Tuesday, June 4, 2024, from 3:12 – 3:18 pm CEST Locations: Poster Area – Poster P-093 and Willem Burger Zaal – Presentation S03-13, respectively Papers on LUMEVOQ®, the Company’s gene therapy for Leber Hereditary Optic Neuropathy (LHON), are also planned to be presented at two other major medical conferences this year: the 2024 Annual Meeting of the American Academy of Ophthalmology (AAO) and the 27th Annual Congress of the European Association for Vision and Eye Research (EVER). The dates and times of the presentations will be confirmed later. On June 5, Magali Taiel, Chief Medical Officer of GenSight Biologics, will speak at the 2nd Multi-Stakeholders Meeting on Clinical Trials for Inherited Retinal Diseases organized by the ERN-EYE, a European Reference Network dedicated to rare eye diseases. Dr. Taiel will also be a speaker at the 2024 Mitochondrial Disease Conference in October, an event organized by the patient advocacy group Mitocon and endorsed by the EURO-NMD, a European Reference Network for rare neuromuscular diseases. About GenSight Biologics GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics’ pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics’ lead product candidate, LUMEVOQ® (GS010; lenadogene nolparvovec), an investigational compound that has not been registered in any country at this stage, was developed for the treatment of Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease affecting primarily teens and young adults that leads to irreversible blindness. Using its gene therapy-based approach, GenSight Biologics’ product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery. View source version on businesswire.com: Contacts GenSight Biologics Chief Financial Officer Ivan Tortet itortet@gensight-biologics.com LifeSci Advisors Investor Relations Guillaume van Renterghem gvanrenterghem@lifesciadvisors.com +41 (0)76 735 01 31 Source: GenSight Biologics View this news release online at:
更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
靶点
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。